This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
America Movil Q2 Earnings Miss, Revenues Up Y/Y on Business Momentum
by Zacks Equity Research
AMX swings to profit in Q2 2025 with surging service revenues and 1.7M new wireless subscribers but misses EPS estimates.
SAP's Q2 Earnings Beat Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
SAP posts 37% EPS growth and 24% cloud revenue surge, but shares slip after mixed Q2 results and currency concerns.
Badger Meter's Q2 Earnings Miss Estimates, Revenues Beat, Stock Down
by Zacks Equity Research
BMI's Q2 sales rise 10% on utility water strength and SmartCover synergies, even as EPS misses expectations.
SLP's Q3 Earnings Top, Sales Up Y/Y, Stock Gains Despite Lowered View
by Zacks Equity Research
Simulation Plus' fiscal Q3 2025 earnings surge 67% on Pro-ficiency gains, but a cut in 2025 outlook shows hurdles in biosimulation and services.
Simulations Plus (SLP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SLP Cuts FY25 Revenue Outlook, Begins Strategic Reorganization
by Zacks Equity Research
Simulations Plus lowers FY25 revenue forecast and restructures operations as biotech headwinds hit services demand.
Rubrik, Inc. (RBRK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rubrik, Inc. (RBRK) delivered earnings and revenue surprises of 54.55% and 7.02%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
Credo Technology's Q4 Earnings and Sales Beat Estimates, Rise Y/Y
by Zacks Equity Research
CRDO posts solid Q4 and FY25 earnings, fueled by surging AI demand. It records a 179.7% quarterly revenue jump on booming product sales.
Nebius' Q1 Loss Widens Y/Y, Revenues Rise on Strong Core AI Growth
by Zacks Equity Research
NBIS reports first-quarter results wherein revenues grow year over year, driven by solid growth in its core AI business.
SLP Advances Predictive Toxicology With DILIsym 11: Shares to Benefit?
by Zacks Equity Research
Simulations Plus unveils DILIsym 11, an upgraded version of its flagship QST platform to advance predictive toxicology and pediatric liver assessment safety.